摘要：Elderly patients with diffuse large B cell lymphoma often are no suitable of standard treat- ment due to comorbidities. Therefore to have the opportunity to use less toxic regimens and of similar efficacy represents a medical need. The combination of rituximab and bendamustine has shown a significant reduction in terms of both hematological and extra-hematological toxicity and a surprising activity both in front line and in relapsing/ refractory setting
